JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1987; 9:1148-1155
© 1987 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenberg, M.
Right arrow Articles by DiMarco, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenberg, M.
Right arrow Articles by DiMarco, J.

Relation between amiodarone and desethylamiodarone plasma concentrations and electrophysiologic effects, efficacy and toxicity

ML Greenberg, BB Lerman, Shipe JR, DL Kaiser, and JP DiMarco

Because the value of monitoring amiodarone plasma concentrations remains undefined, this study was performed to evaluate its role during the management of patients receiving amiodarone. The early electrophysiologic effects of amiodarone were assessed in 40 consecutive patients with coronary artery disease and sustained ventricular tachycardia or fibrillation who underwent electrophysiologic studies and measurement of amiodarone plasma concentration before and 29 +/- 15 (mean +/- SD) days after initiation of therapy. Amiodarone and desethylamiodarone plasma levels did not correlate with changes in either sinus cycle length, QTc interval, ventricular effective refractory period, AH and HV intervals or ventricular tachycardia cycle length. Amiodarone and desethylamiodarone plasma concentrations and the effects of the drug on conduction intervals or right ventricular effective refractory periods were not related to suppression of arrhythmia induction by ventricular stimulation after 1 month of therapy. The relation between amiodarone plasma concentrations and both toxicity and efficacy during long-term therapy were prospectively assessed in a larger series of 114 consecutive patients with either symptomatic supraventricular or ventricular arrhythmias who were followed up on long-term amiodarone therapy for 26 +/- 15 months. Sixty-three patients (55%) had one or more adverse effects attributed to amiodarone. By life-table analysis, 40, 69 and 80% of patients had experienced an adverse reaction after 1, 2 and 3 years of therapy, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 CirculationHome page
S. Le Bouter, A. El Harchi, C. Marionneau, C. Bellocq, A. Chambellan, T. van Veen, C. Boixel, B. Gavillet, H. Abriel, K. Le Quang, et al.
Long-Term Amiodarone Administration Remodels Expression of Ion Channel Transcripts in the Mouse Heart
Circulation, November 9, 2004; 110(19): 3028 - 3035.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
J. Merot, F. Charpentier, J.-M. Poirier, G. Coutris, and J. Weissenburger
Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol
Cardiovasc Res, November 1, 1999; 44(2): 303 - 314.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. Drouin, G. Lande, and F. Charpentier
Amiodarone reduces transmural heterogeneity of repolarization in the human heart
J. Am. Coll. Cardiol., October 1, 1998; 32(4): 1063 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. M. Roden
Risks and Benefits of Antiarrhythmic Therapy
N. Engl. J. Med., September 22, 1994; 331(12): 785 - 791.
[Full Text]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1987 by the American College of Cardiology Foundation.